A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a new study finds.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...

GLP-1 drugs like semaglutide and tirzepatide show promise in treating obesity, with benefits including weight loss and improved metabolic health. However, concerns about long-term safety, cost, and ...

GLP-1 drugs show promise for obesity treatment but raise concerns about long-term use, access and sustainability. Learn more about the future of obesity care.

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented ... “Federico II” gave the glucagon-like peptide-1 (GLP-1) ...

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.

Pfizer's push into obesity will be led by a once-daily formulation of GLP-1 agonist danuglipron as it tries to catch up with Novo Nordisk and Eli Lilly.

While both Wegovy and Ozempic list “headache” as a common side effect that was found during the drugs’ clinical trials, many ...